Orchestra Life Sciences, a technical consultancy specializing in advanced therapy manufacturing solutions, today announced that it has been ranked No. 203 on the 2026 Inc. 5000 list, the annual ranking of the fastest-growing private companies in America.
The Inc. 5000 recognizes the nation’s most successful independent and entrepreneurial businesses based on three-year revenue growth. Orchestra earned its place on the 2026 list following 1,482.8% revenue growth from 2022 to 2025.
Orchestra’s momentum reflects increasing demand for specialized technical and execution expertise across radiopharmaceuticals, cell and gene therapy, biologics, and other complex biopharmaceutical programs. The company partners with organizations across the development and manufacturing lifecycle, providing support from business strategy and early project planning through engineering, capital project execution, regulatory and quality readiness, commissioning and qualification, and operational startup.
Over the past five years, Orchestra has expanded from a four-person team to nearly 100 employees and consultants worldwide. The team brings more than 600 years of collective experience in nuclear medicine and 125 years in cell and gene therapy, helping clients as they move from concept to commercialization.
“Being named to the Inc. 5000 reflects the growth of our team and the trust our partners have placed in Orchestra as they advance increasingly complex therapies,” said Emilie Pelletier, Co-Founder and CEO of Orchestra Life Sciences. “We’ve built Orchestra around deep technical expertise, hands-on execution, and a shared commitment to helping our partners move from strategy to patient impact. This recognition reflects the work of an incredible team that is proud to support organizations developing life-saving therapies for patients who need them.”
Read Also: Acarix Receives Regulatory Approval for the CADScor® System in the UAE
